A molecular imaging technique may prove useful in early assessment of treatment response for cisplatin-resistant ovarian cancer, according to a study published in the 

. Cisplatin is often effective against ovarian cancer when first given, but tumors can become resistant and start growing again.

The study showed F-18 fluorothymidine (F-FLT) PET was able to predict early response to everolimus (a mammalian target of rapamycin inhibitor) in cisplatin-resistant ovarian cancer in mice. The technique should be considered for therapeutic assessment in humans, according to the researchers.

No significant change in tumor F-FLT uptake was observed in the controls. In the everolimus-treated mice, F-FLT standard uptake value decreased by 33% on the second day of treatment and by 66% on the seventh day. There were also changes in tumor volume.

 CT modality focus page provides information, videos, podcasts, and the latest news about industry product developments, trial results, screening guidelines, and protocol guidance that touch on the use of CT across the healthcare continuum, from various cancer screenings, such as lung and colon, to cardiothoracic imaging, to appendicitis, and more.

Diagnostic Imaging Vol 32 No 10

Diagnostic Imaging

A molecular imaging technique may prove useful in early assessment of treatment response for cisplatin-resistant ovarian cancer, according to a study published in the Journal of Nuclear Medicine.

Imaging technique proves useful for ovarian cancer